stockportfolio.pro
Indivior Pharmaceuticals, Inc. P/E Ratio 2022–2025
Indivior Pharmaceuticals, Inc. (INDV) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth -55.5%/yr over 3 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 21.88 | -91.2% |
| FY 2024 | 248.60 | — |
| FY 2023 | — | — |
| FY 2022 | — | — |
Source: Indivior Pharmaceuticals, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for Indivior Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeIndivior Pharmaceuticals, Inc. — frequently asked questions
What is Indivior Pharmaceuticals, Inc.'s price-to-earnings ratio?
Indivior Pharmaceuticals, Inc. (INDV) reported price-to-earnings ratio of 21.88 for fiscal year 2025, per its SEC filings.
How has Indivior Pharmaceuticals, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2022 and 2025, INDV's price-to-earnings ratio declined at roughly 55.5% per year (compound annual rate), from 248.60 to 21.88.
Where does this data come from?
Figures are computed from Indivior Pharmaceuticals, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.